National Institutes of Health

Description

The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that occur in young children with acute myelogenous leukemia (AML). However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95RELA (ependymoma), or NUP98 fusion proteins.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV